Proglumide
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Proglumide
- DrugBank Accession Number
- DB13431
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 334.416
Monoisotopic: 334.189257325 - Chemical Formula
- C18H26N2O4
- Synonyms
- proglumida
- Proglumide
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Gastric ulcer •••••••••••• •••••• Treatment of Intestinal inflammation •••••••••••• •••••• Symptomatic treatment of Intestinal ulcer •••••••••••• •••••• Symptomatic treatment of Gastrointestinal ulceration •••••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism ACholecystokinin receptor type A antagonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- A02BX06 — Proglumide
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resulting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Glutamic acid and derivatives
- Alternative Parents
- N-acyl-alpha amino acids and derivatives / Hippuric acids and derivatives / Alpha amino acid amides / Benzoyl derivatives / N-acyl amines / Tertiary carboxylic acid amides / Secondary carboxylic acid amides / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds show 4 more
- Substituents
- Alpha-amino acid amide / Aromatic homomonocyclic compound / Benzamide / Benzenoid / Benzoic acid or derivatives / Benzoyl / Carbonyl group / Carboxamide group / Carboxylic acid / Glutamic acid or derivatives show 14 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- racemate (CHEBI:32058)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- EPL8W5565D
- CAS number
- 6620-60-6
- InChI Key
- DGMKFQYCZXERLX-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22)
- IUPAC Name
- 4-(dipropylcarbamoyl)-4-(phenylformamido)butanoic acid
- SMILES
- CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=CC=C1
References
- General References
- FDA Thailand Product Information: Milid (proglumide) oral tablets [Link]
- External Links
- ChemSpider
- 4753
- BindingDB
- 50014888
- 8730
- ChEBI
- 32058
- ChEMBL
- CHEMBL316561
- Wikipedia
- Proglumide
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Recruiting Treatment Pancreatic Metastatic Cancer 1 somestatus stop reason just information to hide 1 Completed Other Steatohepatitis, Nonalcoholic 1 somestatus stop reason just information to hide 1 Withdrawn Treatment Pancreatic Metastatic Cancer 1 somestatus stop reason just information to hide 1, 2 Active Not Recruiting Treatment Pain / Pancreas Fibrosis / Safety Issues 1 somestatus stop reason just information to hide 0 Completed Other Cirrhosis of the Liver 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Tablet - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.145 mg/mL ALOGPS logP 1.94 ALOGPS logP 2.14 Chemaxon logS -3.4 ALOGPS pKa (Strongest Acidic) 4.42 Chemaxon pKa (Strongest Basic) -1.2 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 86.71 Å2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 91.56 m3·mol-1 Chemaxon Polarizability 36.7 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 180.00911 predictedDeepCCS 1.0 (2019) [M+H]+ 182.36711 predictedDeepCCS 1.0 (2019) [M+Na]+ 188.91936 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsCholecystokinin receptor type A
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Receptor for cholecystokinin. Mediates pancreatic growth and enzyme secretion, smooth muscle contraction of the gall bladder and stomach. Has a 1000-fold higher affinity for CCK rather than for gastrin. It modulates feeding and dopamine-induced behavior in the central and peripheral nervous system. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system
- Specific Function
- cholecystokinin receptor activity
- Gene Name
- CCKAR
- Uniprot ID
- P32238
- Uniprot Name
- Cholecystokinin receptor type A
- Molecular Weight
- 47840.645 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Drug created at June 23, 2017 20:41 / Updated at August 26, 2024 19:23